Eli Lilly is planning a clinical trial of its diabetes drug Mounjaro in patients six years and older who have obesity, Bloomberg News reported Friday, citing a person familiar with the matter.
The company is already conducting a trial of the drug in children as young as 10 years with type 2 diabetes, according to a U.S. government registry.
Lilly's Danish rival Novo Nordisk has also been conducting a late-stage trial of its drug semaglutide, sold under the brand Ozempic, in children as young as 6 years, according to the registry. Both drugs have seen a surge in demand this year for treatment of diabetes and obesity. Eli Lilly has generated more than $1.5 billion in sales of Mounjaro in the first half of 2023, in just a year after it got approval in the United States.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Eli Lilly targets firms that import and sell imitation Mounjaro onlineEli Lilly filed a complaint with the U.S. International Trade Commission to block companies from importing and selling cheaper versions of its hit drug Mounjaro.
Consulte Mais informação »
US conducts nuclear test in Nevada hours after Russian move to revoke global test banThe U.S. conducted a high-explosive experiment at a nuclear test site in Nevada on Wednesday as tensions flare over Russia's nuclear ambitions.
Consulte Mais informação »
Gray Market for Weight Loss Drug Retatrutide Spreads Online Years Ahead of FDA ApprovalsEli Lilly’s retatrutide will be in clinical trials for the next three years, but knockoff versions already abound
Consulte Mais informação »
Hundreds of online sellers are offering an Eli Lilly weight-loss drug that’s years away from regulatory approval: WSJCiara Linnane is MarketWatch's investing- and corporate-news editor. She is based in New York.
Consulte Mais informação »
Black Market for Weight Loss Drug Retatrutide Spreads Online Years Ahead of FDA ApprovalsEli Lilly’s retatrutide will be in clinical trials for the next three years, but knockoff versions already abound
Consulte Mais informação »
2 Stocks Set to Capitalize on the Surging Weight Loss Drug TrendStocks Analysis by The Tokenist (Timothy Fries) covering: Eli Lilly and Company, Novo Nordisk A/S. Read The Tokenist (Timothy Fries)'s latest article on Investing.com
Consulte Mais informação »